Trazodone therapy of the post-stroke depression
R Raffaele1, L Rampello, I Vecchio
1Institute of Neurological Sciences, University of Catania, Policlinico, Viale A. Doria 6, I-95125 Catania, Italy.
Archives of Gerontology and Geriatrics
|January 1, 1996
Summary
Antidepressant therapy, specifically trazodone, may improve rehabilitation outcomes for stroke survivors experiencing depression. This study found benefits in patients with clinical depression or abnormal Zung scores, and significant gains with abnormal DST results.
Area of Science:
- Neurology
- Psychiatry
- Rehabilitation Medicine
Background:
- Post-stroke depression (PSD) affects 25-60% of patients.
- Antidepressant therapy is known to aid subacute stroke rehabilitation.
- Identifying effective treatments for PSD is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the efficacy of trazodone hydrochloride in improving rehabilitation outcomes for post-stroke patients.
- To assess the impact of antidepressant therapy on activities of daily living (ADL) in stroke survivors with and without depression.
Main Methods:
- A randomized placebo-controlled trial involving 22 stroke rehabilitation patients.
- Patients received either 300 mg/day trazodone-HCl or placebo, starting 30 days post-stroke.
- Depression was assessed via clinical diagnosis, Zung depression scores, and Dexamethasone Suppression Test (DST).
Main Results:
- Patients with clinical depression or abnormal Zung scores showed a trend towards greater ADL improvement with trazodone compared to placebo.
- An abnormal DST was linked to significant ADL score improvements in the trazodone group.
- Trazodone demonstrated potential benefits for post-stroke depression management.
Conclusions:
- Antidepressant treatment with trazodone appears beneficial for improving functional outcomes in stroke survivors with depression.
- The study highlights the importance of diagnosing and treating PSD to enhance rehabilitation.
- Further research is warranted to confirm these findings in larger cohorts.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...